A Phase 2 Study of Zilovertamab Vedotin With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab (R-CHP) in Diffuse Large B-Cell Lymphoma: waveLINE-007

被引：0
|
作者：
David, Lavie [1 ]
Muhit, Ozcan [2 ]
Ewa, Paszkiewicz-Kozik [3 ]
Eva, Gonzalez Barca [4 ]
Min, Kim Tae [5 ]
Benedetta, Puccini [6 ]
Siruo, Wang [7 ]
Rushdia, Yusuf [7 ]
Patricia, Marinello [7 ]
Seog, Kim Won [8 ]
机构：
[1] Hadassah Med Ctr, Jerusalem, Israel
[2] Ankara Univ, Sch Med, Ankara, Turkiye
[3] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland
[4] Barcelona Univ, IDIBELL, Inst Catala Oncol Hosp, Barcelona, Spain
[5] Seoul Natl Univ Hosp, Seoul, South Korea
[6] Azienda Osped Univ Careggi, Florence, Italy
[7] Merck & Co Inc, Rahway, NJ USA
[8] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2023年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P-050
引用
收藏
页码：S31 / S32
页数：2
相关论文
共 50 条
  • [21] Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
    Burke, John M.
    Masaquel, Anthony
    Wang, Rongrong
    Hossain, Farah
    Li, Jia
    Zhou, Summera Qiheng
    Ng, Carmen D.
    Matasar, Matthew
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (11): : e393 - e404
  • [22] Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
    Younes, Anas
    Sehn, Laurie H.
    Johnson, Peter
    Zinzani, Pier Luigi
    Hong, Xiaonan
    Zhu, Jun
    Patti, Caterina
    Belada, David
    Samoilova, Olga
    Suh, Cheolwon
    Leppae, Sirpa
    Rai, Shinya
    Turgut, Mehmet
    Jurczak, Wojciech
    Cheung, Matthew C.
    Gurion, Ronit
    Yeh, Su-Peng
    Lopez-Hernandez, Andres
    Duehrsen, Ulrich
    Thieblemont, Catherine
    Chiattone, Carlos Sergio
    Balasubramanian, Sriram
    Carey, Jodi
    Liu, Grace
    Shreeve, S. Martin
    Sun, Steven
    Zhuang, Sen Hong
    Vermeulen, Jessica
    Staudt, Louis M.
    Wilson, Wyndham
    Fisher, Richard I.
    Engert, Andreas
    Stadtmauer, Edward A.
    Wei, Lee-Jen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15) : 1285 - +
  • [23] Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from the Phase 2 Waveline-004 Study
    Ozcan, Muhit
    Lv, Fangfang
    Norasetthada, Lalita
    Paszkiewicz-Kozik, Ewa
    Schmidt, Joaquin Diaz
    Modi, Dipenkumar
    Fossa, Alexander
    Goyal, Sagun
    Kim, Won Seog
    Lee, Seung Tae
    Santoro, Armando
    Sonmez, Mehmet
    Pathiraja, Kumudu
    Reddy, Nishitha
    Marinello, Patricia
    Song, Yuqin
    BLOOD, 2023, 142
  • [24] Efficacy and Safety of Reduced-Dose Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone ( Pola-R-CHP) in Patients over 80 with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
    Miyao, Kotaro
    Wakayama, Tomoyoshi
    Ozaki, Somi
    Numata, Masaya
    Negishi, Shuto
    Ohara, Fumiya
    Motegi, Kenta
    Wakabayashi, Hiroya
    Sawa, Hitomi
    Sakai, Toshiyasu
    Inagaki, Yuichiro
    Sawa, Masashi
    BLOOD, 2023, 142
  • [25] Addition of venetoclax to rituximab cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large cell B lymphoma
    Calleja, Anne
    HEMATOLOGIE, 2021, 27 (02): : 45 - 46
  • [26] Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older
    Meguro, Akiko
    Ozaki, Katsutoshi
    Sato, Kazuya
    Oh, Iekuni
    Fujiwara, Shinichiro
    Hosonuma, Rie
    Sasazaki, Miyuki
    Kikuchi, Yuji
    Hirata, Yuji
    Yamamoto, Chihiro
    Uesawa, Mitsuyo
    Kobayashi, Hiroyuki
    Matsu, Haruko
    Okabe, Hiroshi
    Uehara, Eisuke
    Nishikawa, Akinori
    Tatara, Raine
    Hatano, Kaoru
    Yamamoto, Chizuru
    Matsuyama, Tomohiro
    Toshima, Masaki
    Ueda, Masuzu
    Ohmine, Ken
    Suzuki, Takahiro
    Mori, Masaki
    Nagai, Tadashi
    Muroi, Kazuo
    Ozawa, Keiya
    LEUKEMIA & LYMPHOMA, 2012, 53 (01) : 43 - 49
  • [27] Impact of occult bone marrow involvement on the outcome of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone therapy for diffuse large B-cell lymphoma
    Arima, Hiroshi
    Maruoka, Hayato
    Nasu, Koji
    Tabata, Sumie
    Kurata, Masayuki
    Matsushita, Akiko
    Imai, Yukihiro
    Takahashi, Takayuki
    Ishikawa, Takayuki
    LEUKEMIA & LYMPHOMA, 2013, 54 (12) : 2645 - 2653
  • [28] Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma
    Hornberger, JC
    Best, JH
    CANCER, 2005, 103 (08) : 1644 - 1651
  • [29] Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
    Micallef, Ivana N. M.
    Maurer, Matthew J.
    Wiseman, Gregory A.
    Nikcevich, Daniel A.
    Kurtin, Paul J.
    Cannon, Michael W.
    Perez, Domingo G.
    Soori, Gamini S.
    Link, Brian K.
    Habermann, Thomas M.
    Witzig, Thomas E.
    BLOOD, 2011, 118 (15) : 4053 - 4061
  • [30] Efficacy and safety of cyclophosphamide, doxorubicin, vincristine, and prednisone regimen with pegylated liposomal doxorubicin±rituximab in treating diffuse large B-cell lymphoma
    Gao, Yuhuan
    Xie, Yan
    Liu, Lihong
    Xue, Hongwei
    Hou, Ming
    Zhang, Mingzhi
    Zhou, Zeping
    Guo, Pengxiang
    Yao, Hongxia
    Shao, Zonghong
    Xie, Xiaobao
    Zhu, Jun
    MINERVA MEDICA, 2021, 112 (02) : 310 - 312
12345